Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2016 Dec 22;17(12):3407–3416. doi: 10.1016/j.celrep.2016.12.031

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities

Kumar Sanjiv, Anna Hagenkort, José Manuel Calderón-Montaño, Tobias Koolmeister, Philip M Reaper, Oliver Mortusewicz, Sylvain A Jacques, Raoul V Kuiper, Niklas Schultz, Martin Scobie, Peter A Charlton, John R Pollard, Ulrika Warpman Berglund, Mikael Altun, Thomas Helleday
PMCID: PMC5638787  PMID: 28009306

(Cell Reports 14, 298–309; January 12, 2016)

In the originally published version of this paper, there were errors in Figures 1, 6, S2, and S6. These errors have since been corrected in the updated versions of the paper and supplemental PDF that are now available online, and they are described in detail below.

In Figure 1F, quantitative data of DMSO and VE-821 were incorrectly presented. In addition, in the first panel of Figure 6A, the wrong ToPro image was displayed by mistake. The figures have been corrected and now appear with the paper online. These corrections do not change the conclusions of the study in any way.

DMSO and VE-821 treatment images were the same for both Figures 1B and S2A and Figures 1E and S2C. There was also a mis-insertion in Figure S2C. While microscopic images for cells treated with 30 nM of AD7762 alone or in combination with VE-821 were displayed in the main figure (Figure 1B, second and fourth panel), a higher concentration of 60 nM of AZD7762 alone or with VE-821 was displayed in Figure S2A. Displaying this additional data in the supplemental figure together with the same DMSO control and VE-821 treated images as shown in Figures 1B and 1E could confuse readers. Moreover, we think it was inappropriate to present data twice even though the data originated from the same experiment, so we have replaced the DMSO and VE-821 images in Figures S2A and S2C.

Lastly, the FACS data in Figure 4A and the first three FACS plots in the upper panel of Figure S6A were the same, as we originally wanted to extend the data for Figure 4 and show more treatments in Figure S6A. We have since removed the 24 hr timepoint from Figure S6A in order to avoid repetition.

The following conflict of interest should have been included in the Acknowledgments section:

“Vertex Pharmaceuticals has applied for a patent where Thomas Helleday and Kumar Sanjiv are listed as inventors (patent numbers WO2015195740 & US2015359797).”

These corrections do not change the conclusions of the study in any way, and the authors regret the errors.

Figure 1.

Figure 1

(corrected)

Figure 1.

Figure 1

(original)

Figure 6.

Figure 6

(corrected)

Figure 6.

Figure 6

(original)

Figure S2.

Figure S2

(corrected)

Figure S2.

Figure S2

(original)

Figure S6.

Figure S6

(corrected)

Figure S6.

Figure S6

(original)

RESOURCES